177 related articles for article (PubMed ID: 34159403)
1. A visual tool inclusive of fetal ultrasound and autopsy findings to reach a balanced approach to counseling on trisomy 18 in early second trimester.
Triunfo S; Bonollo M; Gaffuri P; Viviano M; Satta D; Bergmann M
Arch Gynecol Obstet; 2021 Nov; 304(5):1115-1125. PubMed ID: 34159403
[TBL] [Abstract][Full Text] [Related]
2. Prenatal screening for fetal aneuploidy in singleton pregnancies.
Chitayat D; Langlois S; Douglas Wilson R; ;
J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
[TBL] [Abstract][Full Text] [Related]
3. Contingent first-trimester screening for aneuploidies with cell-free DNA in a Danish clinical setting.
Miltoft CB; Rode L; Ekelund CK; Sundberg K; Kjaergaard S; Zingenberg H; Tabor A
Ultrasound Obstet Gynecol; 2018 Apr; 51(4):470-479. PubMed ID: 28640470
[TBL] [Abstract][Full Text] [Related]
4. Society for Maternal-Fetal Medicine Consult Series #57: Evaluation and management of isolated soft ultrasound markers for aneuploidy in the second trimester: (Replaces Consults #10, Single umbilical artery, October 2010; #16, Isolated echogenic bowel diagnosed on second-trimester ultrasound, August 2011; #17, Evaluation and management of isolated renal pelviectasis on second-trimester ultrasound, December 2011; #25, Isolated fetal choroid plexus cysts, April 2013; #27, Isolated echogenic intracardiac focus, August 2013).
; Prabhu M; Kuller JA; Biggio JR
Am J Obstet Gynecol; 2021 Oct; 225(4):B2-B15. PubMed ID: 34171388
[TBL] [Abstract][Full Text] [Related]
5. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
6. The clinical usefulness of biochemical (free β-hCg, PaPP-a) and ultrasound (nuchal translucency) parameters in prenatal screening of trisomy 21 in the first trimester of pregnancy.
Ziolkowska K; Dydowicz P; Sobkowski M; Tobola-Wrobel K; Wysocka E; Pietryga M
Ginekol Pol; 2019; 90(3):161-166. PubMed ID: 30950006
[TBL] [Abstract][Full Text] [Related]
7. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
Spencer K; Nicolaides KH
BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
[TBL] [Abstract][Full Text] [Related]
8. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
[TBL] [Abstract][Full Text] [Related]
9. The significance of maternal blood pregnancy-associated plasma protein A (PAPP-A) and free beta-subunit of human chorionic gonadotropin (β-hCG) levels for the risk assessment of fetal trisomy 18 during the first prenatal testing between 11 and 13+6 weeks of pregnancy.
Ziolkowska K; Tobola-Wrobel K; Dydowicz P; Zurawski S; Pietryga M; Wysocka E
Ginekol Pol; 2020; 91(12):748-754. PubMed ID: 33447994
[TBL] [Abstract][Full Text] [Related]
10. Prenatal screening for and diagnosis of aneuploidy in twin pregnancies.
Audibert F; Gagnon A; ;
J Obstet Gynaecol Can; 2011 Jul; 33(7):754-67. PubMed ID: 21749753
[TBL] [Abstract][Full Text] [Related]
11. Frontomaxillary facial angle in screening for trisomy 21 at 11 + 0 to 13 + 6 weeks.
Borenstein M; Persico N; Kagan KO; Gazzoni A; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jul; 32(1):5-11. PubMed ID: 18512854
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness, the economic considerations of prenatal screening strategies for trisomy 21 in the Czech Republic.
Dhaifalah I; Májek O
Ceska Gynekol; 2012 Feb; 77(1):39-51. PubMed ID: 22536640
[TBL] [Abstract][Full Text] [Related]
13. How effective is ultrasound-based screening for trisomy 18 without the addition of biochemistry at the time of late first trimester?
Wiechec M; Knafel A; Nocun A; Matyszkiewicz A; Wiercinska E; Latała E
J Perinat Med; 2016 Mar; 44(2):149-59. PubMed ID: 25803072
[TBL] [Abstract][Full Text] [Related]
14. First trimester combined screening for fetal aneuploidies enhanced with additional ultrasound markers: an 8-year prospective study.
Nemescu D; Bratie A; Mihaila A; Navolan D; Tanase A
Ginekol Pol; 2018; 89(4):205-10. PubMed ID: 29781076
[TBL] [Abstract][Full Text] [Related]
15. First-trimester screening for trisomy 21 in Denmark: implications for detection and birth rates of trisomy 18 and trisomy 13.
Ekelund CK; Petersen OB; Skibsted L; Kjaergaard S; Vogel I; Tabor A;
Ultrasound Obstet Gynecol; 2011 Aug; 38(2):140-4. PubMed ID: 21229566
[TBL] [Abstract][Full Text] [Related]
16. Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Bardani E; Nicolaides KH
Ultrasound Obstet Gynecol; 2020 Sep; 56(3):408-415. PubMed ID: 32621353
[TBL] [Abstract][Full Text] [Related]
17. Serum parameters and nuchal translucency in first trimester screening for fetal chromosomal abnormalities.
Zimmermann R; Hucha A; Savoldelli G; Binkert F; Achermann J; Grudzinskas JG
Br J Obstet Gynaecol; 1996 Oct; 103(10):1009-14. PubMed ID: 8863700
[TBL] [Abstract][Full Text] [Related]
18. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
[TBL] [Abstract][Full Text] [Related]
19. [Study on several ultrasound markers combined maternal serum biochemical markers to screen fetal chromosomal aneuploidy at 11 to 13(+)6 weeks of gestation].
Chen X; Chang Y; Cui HY; Ren CC; Yu BY
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):815-8. PubMed ID: 24444556
[TBL] [Abstract][Full Text] [Related]
20. First trimester combined screening in patients with systemic lupus erythematosus: impact of pre-analytical variables on risk assessment.
de Sousa MJR; Ribeiro R; Syngelaki A; Nicolaides KH
Clin Rheumatol; 2019 May; 38(5):1251-1255. PubMed ID: 30919147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
